Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

OPN-Can

Financiado

Cerrado

Investigating the role of OPN CD44 in mechanosensitive tumour invasion using bio...

Investigating the role of OPN CD44 in mechanosensitive tumour invasion using biomimetic models New fields are rapidly emerging that provide exciting and unforeseen opportunities to target disease. This is especially relevant for difficult-to-treat tumours where, despite decades of promising research, successful clinical tra... ver más

09/04/2021

KINGS COLLEGE LOND...

252K€

Presupuesto del proyecto: 252K€

Líder del proyecto

KINGS COLLEGE LONDON No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-04-09

MSCA-IF-2016: Individual Fellowships

I+D

Cerrada hace 8 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

KINGS COLLEGE LONDON

251.86K€ | Lider

THE REGENTS OF THE UNIVERSIT...

LOS ANGELES UCLA SANTA BARBA...

160.13K€ | Participante

Proyectos interesantes

METAFIGHT

Medical Technol...

Biotechnology

4M€ Cerrado

BIO2008-03233

Medical Technol...

Biotechnology

290K€ Cerrado

CANBUILD

Medical Technol...

Biotechnology

2M€ Cerrado

MiTuMi

Medical Technol...

Biotechnology

145K€ Cerrado

PID2021-123013OB-I00

Medical Technol...

Materials Scien...

157K€ Cerrado

ETICAN

Medical Technol...

Materials Scien...

196K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 49 meses Fecha Inicio: 2017-03-03
Fecha Fin: 2021-04-09

Líder del proyecto

KINGS COLLEGE LONDON No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 252K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto New fields are rapidly emerging that provide exciting and unforeseen opportunities to target disease. This is especially relevant for difficult-to-treat tumours where, despite decades of promising research, successful clinical translation of therapeutic options remains intractable. The interrelated fields of mechanobiology and biomimetic engineered disease models have come to the fore in the last decade1–3 and provide a range of opportunities to investigate therapeutic modalities4. These fields have implications for cancer research in three major aspects: 1) dissection of the cell biology governing microenvironmental sensing; 2) development of biomimetic platforms that enhance both the relevance (accuracy) of experimental models and our understanding of tumour biology, especially at the level of microenvironment and cell signalling; and 3) creation of analysis tools to quantify cell sensing. In this MSCA Global Fellowship, I propose a formative advanced research training period at one of the world’s leading institutions of cell and molecular biology and bioengineering (UCB) to learn and apply state-of-the-art biomimetic platforms for a novel tumour biology research project investigating osteopontin(OPN)-CD44 in mechanosensitive glioblastoma invasion. This interdisciplinary collaboration will match the expertise of UCB in biomimetic tumour invasion modelling of the biomechanical and biochemical properties of glioblastoma with my expertise in matricellular biology developed through my prior postdoctoral studies of osteopontin in liver disease. On my return to Europe at KCL, this will provide a springboard to establish an innovative independent research program in promising and underinvestigated tumour biology. I will transfer the knowledge learned at UCB to establish to investigate hepatocellular carcinoma invasion with biomimetic models. This work will ultimately benefit the development of anti-invasive adjuvant therapies.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores